Published in Vaccine Weekly, October 1st, 2008
The new Pharmacor report entitled Malignant Melanoma finds that the launch of Bristol-Myers Squibb/Medarex's ipilimumab, first in the metastatic setting and later in the adjuvant setting, will significantly increase the size of the malignant melanoma drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly